Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Biosynthesis of PGD2 in Vivo
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 9
- Registration Number
- NCT01275300
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 22
- Registration Number
- NCT01250990
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
- Conditions
- ObesityShort StatureGrowth Hormone Deficiency
- Interventions
- Drug: Dose-Establishing Study 1 Niacin 250mgDrug: Dose-Establishing Study 1 Niacin 500mgDrug: Dose-Establishing Study 2 Niacin 500mgDrug: Placebo First
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 37
- Registration Number
- NCT01237041
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1166
- Registration Number
- NCT01228019
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
- Conditions
- Aortocoronary Saphenous Vein Bypass Graft AtherosclerosisIntermediate Saphenous Vein Graft Lesions
- Interventions
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- North Texas Veterans Healthcare System
- Target Recruit Count
- 38
- Registration Number
- NCT01221402
- Locations
- 🇺🇸
VA North Texas Healthcare System, Dallas, Texas, United States
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Abbott
- Target Recruit Count
- 128
- Registration Number
- NCT01200160
- Locations
- 🇲🇽
Site Reference ID/Investigator# 42110, Aguascalientes, Mexico
🇲🇽Site Reference ID/Investigator# 42106, Mexico City DF, Mexico
🇲🇽Site Reference ID/Investigator# 42104, Tijuana, Baja California Norte, Mexico
A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01104519
Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 24
- Registration Number
- NCT01083329
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Purpan University Toulouse Hospital, Toulouse, France
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT01071291
A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT01052493
- Locations
- 🇬🇧
Sir John McMichael Centre for Clinical Studies, Imperial College Healthcare NHS Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.